The global multiple unit pellet systems (MUPS) market has been valued at US$ 3.6 billion in the year 2023, expanding at a CAGR of 3.6% to reach US$ 5.2 billion by the end of 2033. According to a recent study, extended-release dosage forms led the market with a share of about 47.1% in 2023.
Granules, pellets, microspheres, microcapsules, and minitablets are examples of MUPS formulations. MUPS formulations are designed to help people swallow capsules more easily and to improve their physicochemical stability in comparison to suspensions. The MUPS formulations have great bioavailability and are very convenient dosage forms. As they are convenient and user-friendly alternatives to regular tablets, MUPS tablets are rapidly gaining traction across the globe.
MUPS tablets and capsules are the most recommended dosage form due to their non-invasiveness, greater patient compliance, and convenience of drug administration. It is used for disease conditions where repeated long-term drug administration is required, such as gastrointestinal and colon drug delivery.
In addition to being convenient and affordable, it is the safest dosage form. This is expected to fuel the growth in the multiple unit pellet systems market over the forecast period. On the back of these aforementioned factors, the sales of multiple unite pellet systems are expected to surge by 1.6x through 2023 & beyond.
| Attributes | Multiple Unit Pellet Systems Market (From 2018 to 2022) |
|---|---|
| CAGR | 2.7% |
| Market Size - 2017 | US$ 3.138 billion |
| Market Size - 2022 | US$ 3.585 billion |
| Attributes | Multiple Unit Pellet Systems Market (From 2023 to 2033) |
|---|---|
| CAGR | 3.6% |
| Market Size - 2023 | US$ 3.6 billion |
| Market Size - 2033 | US$ 5.2 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per Future Market Insights (FMI), the multiple unit pellet systems market accounted for around 20.1% of the overall US$ 17.3 billion oral controlled release drug market in 2022. The sales of multiple unit pellet systems expanded at a CAGR of 2.6% from 2018 to 2022, owing to the rise in the use of pellets in drug formulations.
Due to their intrinsic benefits, such as the flexibility they provide when compared with conventional forms, and their ability to provide modified release, immediate release, great therapeutic, and taste-masked formulations, MUPS formulations may continue to gain adoption over traditional drug delivery systems (DDS).
In addition to being manufactured in encapsulated pill, or sachet formats, MUPS assist patients in swallowing drugs more easily, a characteristic that is becoming more crucial in targeted medications for pediatric and geriatric populations.
By incorporating taste and odor masking, numerous dose ranges, and the convenience of administration, MUPS makes complex medications reduces the challenge. Backed by this, the multiple unit pellet systems market is anticipated to record a CAGR of 3.5% during the forecast period.
Increasing the use of pellets in drug formulations is expected to create tremendous opportunities in the MUPS market. Due to the numerous benefits pellets offer to both manufacturers and patients, the use of pellets in drug formulations has gained popularity, boosting the demand for multiple unit pellet system (MUPS) formulations.
Pellets are small, spherical, free-flowing particulates with a variety of skills, one of which is the capacity to create MUPS formulations and multi-drug blends, which is a significant advantage.
Pellets have many benefits for production, from flexibility in combining active compounds into oral dosage forms to the product's overall appearance. Pellets provide a variety of release mechanisms, including sustained, gastro-resistant, and controlled release.
Principal Consultant
One of the key factors affecting sales negatively is the complex and challenging production process for MUPS tablets. Manufacturing MUPS tablets involves multiple challenges, including particle segregation during compression and compression forces that could harm the functional coating. Understanding the variables influencing coat damage during pellet compression and segregation during tablet manufacturing is essential.
The fragmentation of pellets during compaction into MUPS tablets is another factor limiting the multiple unit pellet systems market growth. The quality of MUPS tablets may be impacted by the excipients used, as well as homogeneous blends of excipients and pellets. Key players are likely to face challenges while developing MUPS formulations due to the factors mentioned above.
| Category | Formulation |
|---|---|
| Leading Segment | Extended Release Dosage Form |
| Market Share | 47.23% |
| Category | Dosage Form |
|---|---|
| Leading Segment | Capsules |
| Market Share | 47.31% |
Capsules to Remain Highly Sought-after Dosage Form in MUPS Market
Regarding formulation, the extended-release dosage form held the leading market share of about 47.23% in the global market in 2023 and is expected to record a CAGR of 3.5% over the forecast period. As extended-release MUPS tablets are largely used in healthcare institutions, growth in the segment is expected to surge.
While based on dosage form, the capsules segment held a revenue share of 41.3% in 2023 and is poised to expand at a CAGR of 3.3% between 2023 and 2033. Capsules are the most preferred dosage form for MUPS due to advantages such as non-invasiveness and patient compliance. Apart from that, the convenience of drug administration is also considered a significant factor pushing the demand for capsules.
Nearly 69% of Multiple Unit Pellet Systems Sales Come from Proton Pump Inhibitors.
Based on the drug class, the proton pump inhibitors segment held a revenue share of 67.9% in 2023, as MUPS of proton pump inhibitors is largely accepted and available across the globe. Based on distribution channels, hospital pharmacies are expected to be the most preferable distribution channel to access the drug class.
As per FMI, the segment held a significant market share value of 32.9% in 2023 and is expected to account for US$ 1,595.9 million in revenues in 2033 in the MUPS market due to many patient footfalls in hospitals.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Countries | Global Market Share - 2033 |
|---|---|
| North America | 29.6% |
| Europe | 25.9% |
Over 9 out of 10 Multiple Unit Pellet Systems Market Sales in North America to be Account by the United States
The United States dominated North American multiple unit pellet systems market with a total demand share of 91.3% in 2023. Growth in the United States market is expected to surge throughout the forecast period owing to the rising prevalence of gastrointestinal disease and growing demand for gastro-resistant drugs.
As per FMI, the United States is expected to spearhead the growth, with sales expected to increase at a steady pace through 2023 & beyond. Demand for MUPS in the United States is expected to rise at 3.2% CAGR, with the country attributing over 91.9% of total sales in the North American market. The United States MUPS market is expected to reach US$ 1,325.7 million by the end of 2033.
Increasing Research & Development Activities for Efficient Dosage to Push Sales
FMI estimates India held around 48.5% share in South Asia's multiple unit pellet systems market in 2023 and may display a growth rate of 5.4% between 2023 and 2033. With the need for advanced medicine, India's pharmaceutical manufacturers are increasing research and development spending.
The development of efficient dosage forms of already-approved medications, including MUPS formulations, is facilitated by an increase in the research and development of innovative DDS. By increasing patient compliance, MUPS of PPI, for instance, may enhance the demand for MUPS formulations in India.
On the back of these factors, the demand for multiple unit pellet systems in India is expected to accelerate at 5.4% CAGR during the forecast period. India is expected to spearhead the growth in the South Asia market, contributing over 52% of revenue in 2033.
| Countries | Global Market CAGR (From 2023 to 2033) |
|---|---|
| Australia | 1.8% |
| China | 4.4% |
| India | 5.5% |
| United Kingdom | 3.9% |
Favorable Reimbursement Policies in China to Augment Multiple Unit Pellet Systems Demand
China is set to exhibit a CAGR of nearly 4.3% in the East Asia multiple unit pellet systems market during the forecast period. Due to its efficient drug production, China offers medicines at incredibly affordable costs. The prices of top pharmaceutical brands have decreased by an average of 61% in China due to the updated reimbursement policies.
For instance, it has been claimed that pharmaceutical giants Roche and Novartis have agreed to lower the cost of several of their most recent medications in China. This is expected to aid the growth in China market and improve the sales of novel and potent drug formulations, including MUPS tablets and capsules.
According to the study, Germany held around 20.1% share in the Europe MUPS market in 2023 and is projected to display a growth of 4.1% during the forecast period. Consolidation of the pharmaceutical industry in the European countries, including Germany, combined with expansion in outsourcing for MUPS manufacturing, is boosting the multiple unit pellet systems market.
FMI estimates Germany may account for nearly 22% of the demand share in the Europe market, with sales in the country topping a valuation of US$ 279.9 million in 2033. The United Kingdom. It is expected to be the second-leading market in Europe, accounting for around 18.2% of revenue in Europe.
| Countries | Global Market Share (2023) |
|---|---|
| United States | 27.0% |
| Germany | 5.2% |
| Japan | 5.6% |
One of the key factors influencing the rise in the acceptance of multiple unit pellet system (MUPS) formulations is the growth in FDA approvals for pharmaceuticals in the United States. The leading multiple unit pellet system manufacturers are focusing on getting fast-track drug approvals to expand their product portfolio and strengthen their position in the industry.
Recent Developments
The market size of multiple unit pellet systems is to hit US$ 5.2 billion by 2033.
The multiple unit pellet system industry is to record a valuation of US$ 3.6 billion in 2023.
The multiple unit pellet system industry is likely to secure a CAGR of 3.6% through 2033.
The key players in the global multiple unit pellet systems market are AstraZeneca plc, Merck KGaA, Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Galderma SA, and Novartis AG.
Players opt for mergers and acquisitions.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Formulation
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Formulation, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Formulation, 2023 to 2033
5.3.1. Extended Release Dosage Form
5.3.2. Delayed Release Dosage Form
5.3.3. Delayed Release Orodispersible Dosage Form
5.3.4. Others
5.4. Y-o-Y Growth Trend Analysis By Formulation, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Formulation, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dosage Form
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Dosage Form, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dosage Form, 2023 to 2033
6.3.1. Tablets
6.3.2. Capsules
6.3.3. Sachets
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Dosage Form, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Dosage Form, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Drug Class , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class , 2023 to 2033
7.3.1. Anti-Hypertensive
7.3.2. Proton Pump Inhibitors
7.3.3. Antibiotics
7.3.4. Analgesics
7.3.5. Others
7.4. Y-o-Y Growth Trend Analysis By Drug Class , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Drug Class , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Drug Stores
8.3.4. Online Pharmacies
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. South Asia and Pacific
9.3.6. East Asia
9.3.7. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. USA.
10.2.1.2. Canada
10.2.2. By Formulation
10.2.3. By Dosage Form
10.2.4. By Drug Class
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Formulation
10.3.3. By Dosage Form
10.3.4. By Drug Class
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Formulation
11.2.3. By Dosage Form
11.2.4. By Drug Class
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Formulation
11.3.3. By Dosage Form
11.3.4. By Drug Class
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. UK.
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Western Europe
12.2.2. By Formulation
12.2.3. By Dosage Form
12.2.4. By Drug Class
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Formulation
12.3.3. By Dosage Form
12.3.4. By Drug Class
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Russia
13.2.1.3. Czech Republic
13.2.1.4. Romania
13.2.1.5. Rest of Eastern Europe
13.2.2. By Formulation
13.2.3. By Dosage Form
13.2.4. By Drug Class
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Formulation
13.3.3. By Dosage Form
13.3.4. By Drug Class
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Bangladesh
14.2.1.3. Australia
14.2.1.4. New Zealand
14.2.1.5. Rest of South Asia and Pacific
14.2.2. By Formulation
14.2.3. By Dosage Form
14.2.4. By Drug Class
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Formulation
14.3.3. By Dosage Form
14.3.4. By Drug Class
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Formulation
15.2.3. By Dosage Form
15.2.4. By Drug Class
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Formulation
15.3.3. By Dosage Form
15.3.4. By Drug Class
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Formulation
16.2.3. By Dosage Form
16.2.4. By Drug Class
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Formulation
16.3.3. By Dosage Form
16.3.4. By Drug Class
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA.
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Formulation
17.1.2.2. By Dosage Form
17.1.2.3. By Drug Class
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Formulation
17.2.2.2. By Dosage Form
17.2.2.3. By Drug Class
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Formulation
17.3.2.2. By Dosage Form
17.3.2.3. By Drug Class
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Formulation
17.4.2.2. By Dosage Form
17.4.2.3. By Drug Class
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Formulation
17.5.2.2. By Dosage Form
17.5.2.3. By Drug Class
17.5.2.4. By Distribution Channel
17.6. UK.
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Formulation
17.6.2.2. By Dosage Form
17.6.2.3. By Drug Class
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Formulation
17.7.2.2. By Dosage Form
17.7.2.3. By Drug Class
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Formulation
17.8.2.2. By Dosage Form
17.8.2.3. By Drug Class
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Formulation
17.9.2.2. By Dosage Form
17.9.2.3. By Drug Class
17.9.2.4. By Distribution Channel
17.10. Poland
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Formulation
17.10.2.2. By Dosage Form
17.10.2.3. By Drug Class
17.10.2.4. By Distribution Channel
17.11. Russia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Formulation
17.11.2.2. By Dosage Form
17.11.2.3. By Drug Class
17.11.2.4. By Distribution Channel
17.12. Czech Republic
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Formulation
17.12.2.2. By Dosage Form
17.12.2.3. By Drug Class
17.12.2.4. By Distribution Channel
17.13. Romania
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Formulation
17.13.2.2. By Dosage Form
17.13.2.3. By Drug Class
17.13.2.4. By Distribution Channel
17.14. India
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Formulation
17.14.2.2. By Dosage Form
17.14.2.3. By Drug Class
17.14.2.4. By Distribution Channel
17.15. Bangladesh
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Formulation
17.15.2.2. By Dosage Form
17.15.2.3. By Drug Class
17.15.2.4. By Distribution Channel
17.16. Australia
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Formulation
17.16.2.2. By Dosage Form
17.16.2.3. By Drug Class
17.16.2.4. By Distribution Channel
17.17. New Zealand
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Formulation
17.17.2.2. By Dosage Form
17.17.2.3. By Drug Class
17.17.2.4. By Distribution Channel
17.18. China
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Formulation
17.18.2.2. By Dosage Form
17.18.2.3. By Drug Class
17.18.2.4. By Distribution Channel
17.19. Japan
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Formulation
17.19.2.2. By Dosage Form
17.19.2.3. By Drug Class
17.19.2.4. By Distribution Channel
17.20. South Korea
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Formulation
17.20.2.2. By Dosage Form
17.20.2.3. By Drug Class
17.20.2.4. By Distribution Channel
17.21. GCC Countries
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Formulation
17.21.2.2. By Dosage Form
17.21.2.3. By Drug Class
17.21.2.4. By Distribution Channel
17.22. South Africa
17.22.1. Pricing Analysis
17.22.2. Market Share Analysis, 2022
17.22.2.1. By Formulation
17.22.2.2. By Dosage Form
17.22.2.3. By Drug Class
17.22.2.4. By Distribution Channel
17.23. Israel
17.23.1. Pricing Analysis
17.23.2. Market Share Analysis, 2022
17.23.2.1. By Formulation
17.23.2.2. By Dosage Form
17.23.2.3. By Drug Class
17.23.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Formulation
18.3.3. By Dosage Form
18.3.4. By Drug Class
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. AstraZeneca plc
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Merck KGaA
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Galderma SA
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Novartis AG
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. GlaxoSmithKline Plc
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Perrigo Company Plc.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Cipla Ltd.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Astellas Pharma Inc.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Takeda Pharmaceutical Company Ltd.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Eli Lilly and Company
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Dr. Reddy's Laboratories Ltd.
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. Endo International Inc.
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
19.1.14. Mylan Pharmaceuticals Inc.
19.1.14.1. Overview
19.1.14.2. Product Portfolio
19.1.14.3. Profitability by Market Segments
19.1.14.4. Sales Footprint
19.1.14.5. Strategy Overview
19.1.14.5.1. Marketing Strategy
19.1.15. Teva Pharmaceuticals Ltd.
19.1.15.1. Overview
19.1.15.2. Product Portfolio
19.1.15.3. Profitability by Market Segments
19.1.15.4. Sales Footprint
19.1.15.5. Strategy Overview
19.1.15.5.1. Marketing Strategy
19.1.16. AbbVie (Allergan)
19.1.16.1. Overview
19.1.16.2. Product Portfolio
19.1.16.3. Profitability by Market Segments
19.1.16.4. Sales Footprint
19.1.16.5. Strategy Overview
19.1.16.5.1. Marketing Strategy
19.1.17. GlaxoSmithKline Plc
19.1.17.1. Overview
19.1.17.2. Product Portfolio
19.1.17.3. Profitability by Market Segments
19.1.17.4. Sales Footprint
19.1.17.5. Strategy Overview
19.1.17.5.1. Marketing Strategy
19.1.18. Bayer AG
19.1.18.1. Overview
19.1.18.2. Product Portfolio
19.1.18.3. Profitability by Market Segments
19.1.18.4. Sales Footprint
19.1.18.5. Strategy Overview
19.1.18.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Multiple Unit Pellet Systems Market
